Remicade

Celltrion taps Lonza to produce some of its Remicade biosimilar
Celltrion taps Lonza to produce some of its Remicade biosimilar
Biopharma Dive
Celltrion
Lonza
Remicade
biosimilars
Remsima
Flag link:
FTC Issues Civil Investigative Demand to Johnson & Johnson Regarding Remicade
FTC Issues Civil Investigative Demand to Johnson & Johnson Regarding Remicade
Big Molecule Watch
Remicade
JNJ
Pfizer
antitrust
Walgreens
Kroger
Flag link:
FTC investigates J&J contracts regarding the drugmaker's blockbuster Remicade
FTC investigates J&J contracts regarding the drugmaker's blockbuster Remicade
Endpoints
FTC
JNJ
Remicade
antitrust
biosimilars
Pfizer
Inflectra
Flag link:
6 Things Johnson & Johnson Wants You to Know About Its Pharmaceuticals
6 Things Johnson & Johnson Wants You to Know About Its Pharmaceuticals
Motley Fool
JNJ
devices
Remicade
consumer health
immuno-oncology
Flag link:
UnitedHealthcare gives Remicade biosims a leg up with changes to Medicare plans
UnitedHealthcare gives Remicade biosims a leg up with changes to Medicare plans
Fierce Pharma
CMS
UnitedHealthcare
Medicare
JNJ
Remicade
biosimilars
Pfizer
Merck
Flag link:
Pfizer lawsuit could clear path for biosimilars
Pfizer lawsuit could clear path for biosimilars
Medical Marketing and Media
Pfizer
JNJ
Remicade
biosimilars
Inflectra
Flag link:
Judge Denies J&J Motion to Dismiss Pfizer Lawsuit Over Remicade
Judge Denies J&J Motion to Dismiss Pfizer Lawsuit Over Remicade
RAPS.org
Pfizer
JNJ
Remicade
biosimilars
Inflectra
Flag link:
Pfizer Wins Remicade Patent Case Over J&J
Pfizer Wins Remicade Patent Case Over J&J
RAPS.org
Pfizer
Celltrion
JNJ
Janssen
patents
Remicade
Flag link:
Amgen Announces Top-Line Data From Remicade Biosimilar Study
Amgen Announces Top-Line Data From Remicade Biosimilar Study
Yahoo/Zacks.com
Amgen
ABP 710
JNJ
Merck
Remicade
biosimilars
rheumatoid arthritis
Flag link:
Novartis touts effectiveness, safety of autoimmune drug copies
Novartis touts effectiveness, safety of autoimmune drug copies
Yahoo/Reuters
Novartis
biosimilars
JNJ
Remicade
Amgen
Enbrel
autoimmune disease
Flag link:
Can Johnson & Johnson Replace Remicade for $100 Million Upfront?
Can Johnson & Johnson Replace Remicade for $100 Million Upfront?
Motley Fool
JNJ
Remicade
TD-1473
Theravance
JAK inhibitors
inflammatory bowel disease
Flag link:
Remicade biosims from Pfizer, Merck unlikely to turn the tide in 2018: analyst
Remicade biosims from Pfizer, Merck unlikely to turn the tide in 2018: analyst
Fierce Pharma
Remicade
biosimilars
Pfizer
Merck
JNJ
Flag link:
Biosimilars Council Sides with Pfizer in Antitrust Dispute with J&J
Biosimilars Council Sides with Pfizer in Antitrust Dispute with J&J
JD Supra
biosimilars
Pfizer
JNJ
antitrust
Remicade
Inflectra
Flag link:
J&J’s move to cut Remicade price cost some big bucks, but guarded against Pfizer’s copycat
J&J’s move to cut Remicade price cost some big bucks, but guarded against Pfizer’s copycat
Endpoints
JNJ
Remicade
drug pricing
Pfizer
biosimilars
Flag link:
The 2018 biosimilar litigation landscape: A primer
The 2018 biosimilar litigation landscape: A primer
BioPharma Dive
biosimilars
FDA
Neupogen
Neulasta
Remicade
Epogen
Enbreal
Humira
Avastin
Herceptin
Flag link:
Pfizer Not Planning US Launch of its Second Remicade Biosimilar Approved by FDA
Pfizer Not Planning US Launch of its Second Remicade Biosimilar Approved by FDA
RAPS.org
Pfizer
biosimilars
Remicade
Ixifi
Inflectra
JNJ
Flag link:
Pfizer's second biosimilar of J&J's Remicade wins U.S. FDA approval
Pfizer's second biosimilar of J&J's Remicade wins U.S. FDA approval
Yahoo/Reuters
Pfizer
biosimilars
JNJ
Remicade
Ifixi
rheumatoid arthritis
Crohn's Disease
Flag link:
[forum discussion]Pfizer Jumps the Shark over Biosimilar Failure
[forum discussion]Pfizer Jumps the Shark over Biosimilar Failure
Cafepharma Message Boards
Pfizer
biosimilars
Inflectra
Remicade
JNJ
Flag link:
Pfizer Accuses J&J of Anticompetitive Business Practices over Remicade Biosimilar
Pfizer Accuses J&J of Anticompetitive Business Practices over Remicade Biosimilar
JD Supra
Pfizer
JNJ
Remicade
biosimilars
anticompetitive practices
Celltrion
Flag link:
As Johnson & Johnson holds off U.S. biosims, Remicade's European market share falls to 50%: report
As Johnson & Johnson holds off U.S. biosims, Remicade's European market share falls to 50%: report
Fierce Pharma
JNJ
biosimilars
Remicade
Europe
anti-TNF
Flag link:

Pages